Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 2, 1997, Pages 140-146

  Carlson, L ^a   Goren, M P ^b   Bush, D A ^b   Griener, J C ^a   Quigley, R ^a   Tkaczewski, I ^c   Kamen, B A ^a   Weitman, S D ^d,e  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

^d CTRC Institute for Drug Development   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Hemodialysis; Ifosfamide; Pediatrics; Pharmacokinetics; Wilms' tumor

Indexed keywords

4 HYDROPEROXYIFOSFAMIDE; CHLOROACETALDEHYDE; DRUG METABOLITE; IFOSFAMIDE;

ARTICLE; BLOOD TOXICITY; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY AGENESIS; KIDNEY FAILURE; NEPHROBLASTOMA; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0031907025     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050720     Document Type: Article

References (36)

1. Pinkerton CR, Rogers H, James C, Bowman A, Barbor PRH, Eden OB, Pritchard J (1985) A phase II study of ifosfamide in children with recurrent solid tumors. Cancer Chemother Pharmacol 15: 258
2. Tournade MF (1989) A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor. Cancer Chemother Pharmacol [Suppl] 24: S31
3. Pratt CB, Douglass EC, Etcubanas EL, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson El, Wilimas JA (1989) Ifosfamide in pediatric malignant solid tumors. Cancer Chemother Pharmacol [Suppl] 24: S24
4. Pinkerton CR, Pritchard J (1989) A phase II study of ifosfamide in paediatric solid tumors. Cancer Chemother Pharmacol [Suppl] 24: S13
5. Schwartzman E, Scopinaro M, Angueyra N (1989) Phase II study of ifosfamide as a single drug for relapsed paediatric patients. Cancer Chemother Pharmacol [Suppl] 24: S11
6. Pratt CB, Meyer WH, Douglass EC, Bowman L, Wilimas J, Ochs J, Marina N, Avery L, Thompson EI (1993) A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors. Cancer 71: 3661
7. De Kraker J, Voute PA (1993) Ifosfamide in renal tumors: contradictory? Am J Pediatr Hematol Oncol [Suppl] 15: S72
8. Pinkerton CR (1993) Ifosfamide in relapsed Wilms' tumor. Am J Pediatr Hematol Oncol [Suppl] 15: S75
9. Pappo AS, Etcubanas E, Santana VM, Rao BN, Kun LE, Fontanesi J, Roberson PK, Bowman LC, Crist WM, Shapiro DN (1993) A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 71: 2119
10. Pratt CB, Douglass EC, Kovnar EH, Heideman R, Kun L, Avery L, Kellie SJ (1993) A phase I study of ifosfamide given on alternate days to treat children with brain tumors. Cancer 71: 3669
11. Rung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, Krischer JP, Murphy SB, Pratt CB, Toledano S, Wiley JM, Yu AL (1995) Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a pediatric oncology group phase I/II study. J Pediatr Hematol Oncol 17: 265
12. Van Hoff J, Grier HE, Douglass EC, Green DM (1995) Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. Cancer 75: 2966
13. Marina NM, Rodman JH, Murry DJ, Shema SJ, Bowman LC, Jones DP, Furman W, Meyer WH, Pratt CB (1994) Phase 1 study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst 86: 544
14. Crooks GM, Sato JK (1995) Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 17: 34
15. Skinner R, Sharkey IM, Pearson ADJ, Craft AW (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11: 173
16. Wagner VT, Heydrich D, Bartels H, Hohorst HJ (1980) Einfluß von leberparenchymschaden, niereninsuffizienz und hamodialyse auf die pharmakokinetik von cyclophosphamid und seinen aktivierten metaboliten. Arzneim Forsch 30: 1588
17. Bagley CM, Bostick FW, DeVita VT (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226
18. Mouridsen HT, Jacobsen E (1975) Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 36: 409
19. Talha MR, Rogers HJ (1984) Rapid gas Chromatographic determination of ifosfamide in biologic fluids. J Chromatogr 311: 194
20. Kobayashi K, Tanaka M, Kawai S (1980) Gas Chromatographic determination of low molecular weight carbonyl compounds in aqueous solutions as their 0-(2,3,4,5,6-pentafluorobenzyl) oximes. J Chromatogr 187: 413
21. Arndt CA, Balis FM, McCully CL, Colvin OM, Poplack DG (1988) Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 48: 2113
22. Alarcon RA, Meienhofer J, Atherton E (1972) Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclo-phosphamide. Cancer Res 32: 2519
23. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1996) Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administrations. Cancer Chemother Pharmacol 38: 147
24. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1995) Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 31A: 785
25. Boddy AV, Cole M, Pearson ADJ, Idle JR (1995) The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 36: 53
26. Prasad VK, Corlett SA, Abaasi K, Heney D, Lewis I, Chrystyn H (1994) Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother Pharmacol 34: 447
27. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1993) Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 53: 3758
28. Ninane J, Baurain R, Kraker J, Ferster A, Trouet A, Cornu G (1989) Alkylating activity in serum, urine, and csf following high-dose ifosfamide in children. Cancer Chemother Pharmacol 24: S2
29. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629
30. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157
31. Goren MP (1991) Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid Chromatography. J Chromatogr 570: 351
32. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28: 455
33. Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet 2: 1219
34. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33: 36
35. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26: 439
36. Alexander SR, Harmon WE, Jabs K (1994) Dialysis in children. In: Henrich WL (ed) Principles and practice of dialysis. Williams and Wilkins. Baltimore, pp 393-425